Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Study Summary

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.

Conditions

Multiple Myeloma

Interventions / Drugs

Carfilzomib Venetoclax Dexamethasone

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment120 participants

Primary Completion—

Lead SponsorAbbVie

Data Retrieved2026-04-11 02:51:51.324759+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.